Key facts
- Metabix Biotech’s last known valuation is $8.2M (Mar 2026).
- It has raised $2.3M; the latest was Early Stage VC ($2.3M) in Mar 2026.
- Notable investors include AIR Capital, Angel Hub, Dalus Capital, Danta Fund, EWA Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Metabix Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Metabix Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Metabix Biotech
Developer of a predictive biotechnology software designed to prevent disease outbreaks in plants, animals, and humans. The company specializes in environmental pathogen detection, offering advanced hardware and AI-driven software to assess infection risks, enabling clients with early warnings and proactive measures to improve safety, productivity, and overall well-being.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 10
- Website
- metabixbiotech.com/
- Ownership
- Privately Held (backing)
Metabix Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metabix Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metabix Biotech in its N-PORT filings yet. We sweep new filings monthly.